A group of 485 independently owned pharmacies nationwide has sued OptumRx, the successor company to Catamaran Corp. through a merger, claiming they were low-balled on reimbursements based on outdated pricing data.
The complaint claims that the company earns $60 billion dollars a year managing 1.2 billion prescriptions annually.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
